Efficient adenoviral transfer of NF-kappaB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis.

Détails

ID Serval
serval:BIB_EA98D2708E09
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Efficient adenoviral transfer of NF-kappaB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis.
Périodique
International Journal of Cancer
Auteur⸱e⸱s
Bakker T.R., Reed D., Renno T., Jongeneel C.V.
ISSN
0020-7136[print], 0020-7136[linking]
Statut éditorial
Publié
Date de publication
01/1999
Volume
80
Numéro
2
Pages
320-323
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
It has been suggested that the in vitro cytotoxicity of tumor necrosis factor (TNF) toward a number of transformed cell lines could make it a useful agent for anti-tumor therapy. However, many tumor cell lines are resistant to TNF-induced cell death. It has been shown that transcription factors of the NF-kappaB family, which are themselves activated by TNF, could protect cells against apoptotic cell death. To test whether melanoma cells, which are normally resistant to TNF-mediated killing, can be made susceptible by inhibiting the activation of NF-kappaB, we generated a recombinant adenovirus expressing a dominant mutant form of IkappaB alpha under the control of a CMV promoter. We show here that adenovirus-mediated inhibition of NF-kappaB function rendered melanoma cells susceptible to the cytotoxic effects of TNF, and thus that NF-kappaB-inhibiting adenoviruses could become useful adjuvants in TNF-based anti-tumor therapies.
Mots-clé
Adenoviridae/genetics, Apoptosis/drug effects, DNA-Binding Proteins/therapeutic use, Humans, I-kappa B Proteins, Melanoma/drug therapy, Melanoma/pathology, NF-kappa B/antagonists &amp, inhibitors, Recombinant Proteins/therapeutic use, Transfection, Tumor Cells, Cultured, Tumor Necrosis Factor-alpha/therapeutic use
Pubmed
Web of science
Création de la notice
24/01/2008 16:39
Dernière modification de la notice
20/08/2019 17:13
Données d'usage